Antidepressant effects of
ketamine in depressed patients
by
Berman RM, Cappiello A, Anand A, Oren DA,
Heninger GR, Charney DS, Krystal JH
Abraham Ribicoff Center
Clinical Neuroscience Research Unit
Connecticut Mental Health Center,
New Haven, USA.
Biol Psychiatry 2000 Feb 15; 47(4):351-4

ABSTRACT

Background: A growing body of preclinical research suggests that brain glutamate systems may be involved in the pathophysiology of major depression and the mechanism of action of antidepressants. This is the first placebo-controlled, double-blinded trial to assess the treatment effects of a single dose of an N-methyl-D-aspartate (NMDA) receptor antagonist in patients with depression.Methods: Seven subjects with major depression completed 2 test days that involved intravenous treatment with ketamine hydrochloride (.5 mg/kg) or saline solutions under randomized, double-blind conditions. Results: Subjects with depression evidenced significant improvement in depressive symptoms within 72 hours after ketamine but not placebo infusion (i.e., mean 25-item Hamilton Depression Rating Scale scores decreased by 14 +/- SD 10 points vs. 0 +/- 12 points, respectively during active and sham treatment).Conclusions: These results suggest a potential role for NMDA receptor-modulating drugs in the treatment of depression.

PCP
NMDA
Ketamine
Glutamate
Phencyclidine
Neurotrophins
Ketamine.com
Neuroprotectants
NMDA antagonists
Fentanyl and ketamine
Ketamine and cognition
21st century antidepressants
Anaesthesia and anaesthetics
Ketamine (Ketalar ) : structure
Ketamine therapy for alcoholics
Ketamine is enjoyable and impairs response inhibition

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family